Iofina PLC (AIM:IOF, OTC:IOFNF) CEO Dr Tom Becker takes Proactive's Stephen Gunnion through the company’s strong 2024 financial performance and its strategic outlook for 2025. The company reported record revenue, marking the seventh consecutive year of revenue growth. According to Becker, “We just posted our 2024 results. Record revenue of above $54 million… record iodine production… and EBITDA of over $7.6 million.”
A significant highlight from 2024 was the 31% year-on-year increase in iodine derivative sales, driven by a targeted marketing effort and expansion in applications such as biocides, pharmaceuticals, and animal health. Iofina has also launched a new animal feed derivative in early 2025 through its chemical division.
On the growth front, Becker confirmed the IO#11 plant remains on track for commissioning in Q3 2025, with IO#12 under evaluation. The company’s capital investment totalled approximately $9.5 million. Becker emphasised the company’s ability to rapidly construct new plants with favourable returns.
Iodine prices have remained stable above $70/kg, and the company expects this trend to continue through 2025. Iofina anticipates another record year for iodine production, with projections depending on IO#11’s operational timeline.
Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content.
#Iofina #IodineProduction #TomBecker #ChemicalIndustry #SpecialtyChemicals #InvestorUpdate #2024Results #IO11 #RevenueGrowth #IodineDerivatives #AnimalHealth #Biocides #Pharmaceuticals #CapitalInvestment #ProactiveInvestors
